Welcome to Diopsys, Inc.
As the world leader in modern visual electrophysiology, Diopsys, Inc. has done more than any other company to advance the use of electroretinography (ERG) and visual evoked potential (VEP) in the eye care practice. The company’s unique, patented technology provides eye care professionals with objective, functional information about the health of the vision system to aid in the early detection of vision disorders, and post-treatment tracking for enhanced patient management.
Results from these tests are not just for rare diseases, but also for the management of more common disorders like diabetic retinopathy, retinal concerns obscured by media opacities, glaucoma, and optic neuritis. See our “Resources” section for research and articles supporting the many clinical benefits visual electrophysiology can provide.
The VEP results correlated significantly with the severity of visual field damage, but the results were obtained objectively, which helps give eye care specialists more confidence in the findings.
Pattern ERG is a technology that allows us to have earlier diagnosis or confirmation of glaucoma than anything else that we currently use.
In my 40 some years in this business, this is the first time that we’ve been able to get real, objective evidence of how the retina’s doing in a host of conditions.
In my world, I’m testing patients with cataracts, glaucoma, macular degeneration, and retinal pathology. It’s not your typical assumption of what electrophysiology would be, and I think that’s the beauty of the Diopsys® NOVA™ system. It’s allowing doctors like me to be able to take this technology and actually elucidate a lot of these problems in our practice.
A game-changer in glaucoma diagnostics (Diopsys®NOVA™) is technology that utilizes ERG and VEP in-office to detect ganglion cell suffering prior to damage that is permanent and irreversible.
The holy grail for glaucoma or all forms of progressive optic neuropathy is to be able to answer, ‘is the problem in the retina or is the problem in the visual pathway behind the eye?’ Now there’s a way of doing this that we didn’t have before (with the Diopsys® NOVA™). Not only is it helping us understand today’s patient, but it’s going to help us develop new therapies that will save a lot of morbidity and save a lot of sight in our own lifetime.
We are using the Diopsys® NOVA™ ERG and VEP Vision Testing System in a variety of patients. We’re using it in patients with low tension glaucoma where it’s difficult to ascertain what’s happening because they have a “normal” pressure. They may have a totally normal visual field, but they have a very abnormal optic disc, so in those patients, this electrophysiologic testing is of great help.
Before we had our Diopsys® NOVA™ ERG and VEP Vision Testing System, I would be hard-pressed to send somebody for an ERG. But with this office-based device, not only can we do these tests more efficiently, now we can explore and handle diseases that we never thought of doing electrophysiology for.
A study in Documenta Ophthalmologica showed the Diopsys® NOVA™ is a reliable and reproducible device; making this technology extremely useful for detection of pathologies affecting the entire visual pathway.
Glaucoma is one of our biggest practice growth drivers the last couple of years. The best way to treat glaucoma is to catch it as early as possible in order to alter the disease curve. The Diopsys® NOVA™ Vision Testing System fits into our diagnostic glaucoma suite so elegantly and clinically.
The SD-tVEP results (from the Diopsys® NOVA™) correlated significantly with the severity of visual field damage, but the results were obtained objectively, which helps give eye care specialists more confidence in the findings.
The Diopsys® NOVA™ ERG and VEP Vision Testing System has played an important role in helping us determine how well a patient is responding to therapy. When we lower eye pressure enough or treat these patients appropriately, we can see improvement in function. This technology is very sensitive. When we measure structure, say with OCT, we may not see the improvement.